Clofazimine-induced premaculopathy in a vitiliginous patient

A 26-year-old male vitiliginous patient presented with decreased visual acuity because of a central scotoma in the left eye with no significant retinal changes on fundus examination. In this case report, a diagnosis of possible drug-induced premaculopathy was made, and the drugs were withdrawn. On t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasturi, Nirupama, Srinivasan, Renuka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020777/
https://www.ncbi.nlm.nih.gov/pubmed/27651714
http://dx.doi.org/10.4103/0976-500X.189685
_version_ 1782453263716581376
author Kasturi, Nirupama
Srinivasan, Renuka
author_facet Kasturi, Nirupama
Srinivasan, Renuka
author_sort Kasturi, Nirupama
collection PubMed
description A 26-year-old male vitiliginous patient presented with decreased visual acuity because of a central scotoma in the left eye with no significant retinal changes on fundus examination. In this case report, a diagnosis of possible drug-induced premaculopathy was made, and the drugs were withdrawn. On the follow-up, after 3 months, the visual acuity in the left eye gradually improved. Early suspicion of drug-induced maculopathy and withdrawal of the drug may prevent the progression of maculopathy.
format Online
Article
Text
id pubmed-5020777
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-50207772016-09-20 Clofazimine-induced premaculopathy in a vitiliginous patient Kasturi, Nirupama Srinivasan, Renuka J Pharmacol Pharmacother Case Report A 26-year-old male vitiliginous patient presented with decreased visual acuity because of a central scotoma in the left eye with no significant retinal changes on fundus examination. In this case report, a diagnosis of possible drug-induced premaculopathy was made, and the drugs were withdrawn. On the follow-up, after 3 months, the visual acuity in the left eye gradually improved. Early suspicion of drug-induced maculopathy and withdrawal of the drug may prevent the progression of maculopathy. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5020777/ /pubmed/27651714 http://dx.doi.org/10.4103/0976-500X.189685 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Case Report
Kasturi, Nirupama
Srinivasan, Renuka
Clofazimine-induced premaculopathy in a vitiliginous patient
title Clofazimine-induced premaculopathy in a vitiliginous patient
title_full Clofazimine-induced premaculopathy in a vitiliginous patient
title_fullStr Clofazimine-induced premaculopathy in a vitiliginous patient
title_full_unstemmed Clofazimine-induced premaculopathy in a vitiliginous patient
title_short Clofazimine-induced premaculopathy in a vitiliginous patient
title_sort clofazimine-induced premaculopathy in a vitiliginous patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020777/
https://www.ncbi.nlm.nih.gov/pubmed/27651714
http://dx.doi.org/10.4103/0976-500X.189685
work_keys_str_mv AT kasturinirupama clofazimineinducedpremaculopathyinavitiliginouspatient
AT srinivasanrenuka clofazimineinducedpremaculopathyinavitiliginouspatient

Ejemplares similares